Your browser doesn't support javascript.
loading
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.
Meijer, A J M; Diepstraten, F A; Langer, T; Broer, L; Domingo, I K; Clemens, E; Uitterlinden, A G; de Vries, A C H; van Grotel, M; Vermeij, W P; Ozinga, R A; Binder, H; Byrne, J; van Dulmen-den Broeder, E; Garrè, M L; Grabow, D; Kaatsch, P; Kaiser, M; Kenborg, L; Winther, J F; Rechnitzer, C; Hasle, H; Kepak, T; Kepakova, K; Tissing, W J E; van der Kooi, A L F; Kremer, L C M; Kruseova, J; Pluijm, S M F; Kuehni, C E; van der Pal, H J H; Parfitt, R; Spix, C; Tillmanns, A; Deuster, D; Matulat, P; Calaminus, G; Hoetink, A E; Elsner, S; Gebauer, J; Haupt, R; Lackner, H; Blattmann, C; Neggers, S J C M M; Rassekh, S R; Wright, G E B; Brooks, B; Nagtegaal, A P; Drögemöller, B I; Ross, C J D.
Afiliación
  • Meijer AJM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. a.j.m.meijer-16@prinsesmaximacentrum.nl.
  • Diepstraten FA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Langer T; Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
  • Broer L; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Domingo IK; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
  • Clemens E; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Uitterlinden AG; Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • de Vries ACH; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van Grotel M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Vermeij WP; Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Ozinga RA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Binder H; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Byrne J; Oncode Institute, Utrecht, The Netherlands.
  • van Dulmen-den Broeder E; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Garrè ML; Oncode Institute, Utrecht, The Netherlands.
  • Grabow D; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Kaatsch P; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
  • Kaiser M; Boyne Research Institute, Drogheda, Ireland.
  • Kenborg L; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Winther JF; VU Medical Center, Amsterdam, The Netherlands.
  • Rechnitzer C; Department of Neurooncology, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Hasle H; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Kepak T; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Kepakova K; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Tissing WJE; Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • van der Kooi ALF; Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Kremer LCM; Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark.
  • Kruseova J; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Pluijm SMF; Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
  • Kuehni CE; University Hospital Brno, Brno, Czech Republic.
  • van der Pal HJH; International Clinical Research Center (FNUSA-ICRC), Brno, Czech Republic.
  • Parfitt R; University Hospital Brno, Brno, Czech Republic.
  • Spix C; International Clinical Research Center (FNUSA-ICRC), Brno, Czech Republic.
  • Tillmanns A; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Deuster D; Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Matulat P; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Calaminus G; Department of Obstetrics and Gynecology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Hoetink AE; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Elsner S; Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Gebauer J; Department of Children Hemato-Oncology, Motol University Hospital Prague, Prague, Czech Republic.
  • Haupt R; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Lackner H; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Blattmann C; Pediatric Hematology and Oncology, University Children's Hospital Bern, University of Bern, Bern, Switzerland.
  • Neggers SJCMM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Rassekh SR; Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Wright GEB; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
  • Brooks B; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Nagtegaal AP; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
  • Drögemöller BI; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
  • Ross CJD; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
NPJ Precis Oncol ; 5(1): 64, 2021 Jul 14.
Article en En | MEDLINE | ID: mdl-34262104
In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts (n = 192 and 188, respectively) (combined cohort: P = 5.3 × 10-10, OR 3.11, 95% CI 2.2-4.5). Modulating TCERG1L expression in cultured human cells revealed significantly altered cellular responses to cisplatin-induced cytokine secretion and toxicity. These results contribute to insights into the genetic and pathophysiological basis of cisplatin-induced ototoxicity.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: NPJ Precis Oncol Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: NPJ Precis Oncol Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido